François Ravenelle, PhD
Founder & CEO
Dr. Ravenelle is championing the comeback of cannabinoid receptor-1 (CB1) blockers at Inversago Pharma Inc.
An entrepreneur with 16 years of industrial R&D experience, his background includes pharmaceutical development from discovery through NDA approval.
Jamie Stiff, BSc, MBA
Managing Director, Genesys Capital
Mr. Stiff is Managing Director at Genesys Capital, a life science focused venture firm.
Over his career, he has been responsible for investments in several early stage portfolio companies that cross a multitude of clinical disciplines and technology areas.
Maxime Ranger, PhD, MBA
General Partner, AmorChem
Dr. Ranger is a General Partner at AmorChem, an early-stage venture capital fund specialized in life science.
As a serial entrepreneur in the biotech industry, his expertise includes drug development across a range of therapeutic indications including oncology, hepatology, gastroenterology and metabolic conditions, such as NASH, Prader-Willi Syndrome, type-2 diabetes and obesity.
Dr. Ranger is a co-author of 30+ scientific publications in international peer-reviewed journals.